Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401
in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell
Non-Hodgkin's Lymphoma.